Athenex Inc (NQ: ATNX )

13.50 USD -0.44 (-3.16%)

Streaming Delayed Price Updated: 5:25 AM EST, Jan 27, 2021 Add to My Watchlist

Price and Volume

Volume	481
Open	13.94
Bid (Size)	13.50 (8)
Ask (Size)	14.00 (1)
Prev. Close	13.94
Today's Range	13.50 - 13.94
52wk Range	5.630 - 15.67
Shares Outstanding	63,543,559
Dividend Yield	N/A

Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News

CEO Dr. Johnson Lau Recuperating from COVID at Home

January 25, 2021

CEO Dr. Johnson Lau Contracts COVID-19

January 08, 2021

Performance

YTD	+19.26%	+19.26%
1 Month	+18.42%	+18.42%
3 Month	+18.63%	+18.63%
6 Month	+26.88%	+26.88%
1 Year	-2.74%	-2.74%

More News

Athenex to Present at the 39th Annual J.P. Morgan Healthcare Conference

January 05, 2021

Almirall announces FDA approval of Klisyri® (tirbanibulin), a new innovative topical treatment for actinic keratosis

December 15, 2020

Athenex Announces FDA Approval of Klisyri® (Tirbanibulin) for the Treatment of Actinic Keratosis on the Face or Scalp

December 15, 2020

Athenex Presents Updated Phase 3 Data on Survival and Tolerability Associated with Oral Paclitaxel and Encequidar in Patients with Metastatic Breast Cancer

December 09, 2020

Athenex Pharmaceutical Division and Ingenus Pharmaceuticals Announce Availability of Liquid, Ready to Dilute Cyclophosphamide

December 02, 2020

Athenex Announces Data on Oral Paclitaxel and Encequidar to be Presented at the 2020 San Antonio Breast Cancer Symposium (SABCS)

November 17, 2020

Implied XBI Analyst Target Price: $202

January 19, 2021

Athenex, Inc. Reports Third Quarter Ended September 30, 2020 Financial Results and Provides Corporate Update

November 05, 2020

First Week of March 19th Options Trading For Athenex (ATNX)

January 15, 2021

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.